BlueRock Therapeutics’ Post

If you have missed our latest podcast episode featuring Paul Ashley from NFP, here’s your chance to listen to it! In this insightful discussion, we explore strategies for optimizing pharmacy benefits and reducing costs for self-funded plans. Key topics include: • Carving In vs. Carving Out PBMs: Understanding the pros and cons of each approach. • Managing Specialty Drugs and Gene Therapy Costs: Effective strategies for cost control. • Leveraging Data for Transparency and Savings: How to use data to drive better decisions and achieve greater savings. If you’re looking for actionable insights to lower costs and enhance efficiency, this episode is a must-listen! Check it out on HCAA’s PodBean today! 🎧: https://bit.ly/3zOp2gt

If you have missed our latest podcast episode featuring Paul Ashley from NFP, here’s your chance to listen to it! In this insightful discussion, we explore strategies for optimizing pharmacy benefits and reducing costs for self-funded plans. Key topics include: • Carving In vs. Carving Out PBMs: Understanding the pros and cons of each approach. • Managing Specialty Drugs and Gene Therapy Costs: Effective strategies for cost control. • Leveraging Data for Transparency and Savings: How to use data to drive better decisions and achieve greater savings. If you’re looking for actionable insights to lower costs and enhance efficiency, this episode is a must-listen! Check it out on HCAA’s PodBean today! 🎧: https://bit.ly/3NdPbbK

Join us on December 12th to learn how RTSM can be tailored to meet precision medicine’s unique challenges of expiry, visit & personalized shipment management! Register here for the discussion: https://lnkd.in/eqxxZq7J   Explore case studies sharing Perceptive Inc.'s experience of delivering: -Cell and gene therapy (CGT) studies  -Radiopharmaceutical studies   Plus, learn how a good RTSM can support associated challenges of: -Oncology and rare disease designs -Innovative trial designs of adaptive & master protocols -Medication pooling and JIT -Sourcing differences -High unblinding risk

Timothy J. Taxter, M.D. presenting now our new Endometrial prognosticator. Here we show how we divide NSMP into a new high risk subtype that is characterized by low levels of expression of ESR1 and high genomic fragmentation. Session PO.CL01.10 - Predictive Biomarkers 5 , Section 43 6416 / 28 - Early stage endometrioid endometrial cancer recurrence risk stratification using a machine learning RNA-seq gene expression signature                          #Tempus #AACR24

Understanding the unique challenges facing Biotech sponsors who are embarking on IO clinical studies, IQVIA Biotech’s Erin Finot, MS, MBA recently authored a compelling white paper reviewing IO innovation in cell and gene therapies. If you’re heading to ASCO, this is your chance to meet with our VP of Immuno-Oncology and Cell and Gene Therapy, and discuss your specific clinical challenges. Discover more. https://bit.ly/4dRSvp4 #ASCO24

Precision and patient-focus are key for cell, gene and immunotherapy clinical studies. At Advanced Clinical, our team understands the complexities of these trials. Learn how our team can make sure your immunotherapy study is set up for success: https://hubs.la/Q02z-3Vm0 #Immunotherapy #CellGeneTherapy #CellTherapy #GeneTherapy #ClinicalTrials

From leukapheresis to product release, Kite reduced the TAT from 16 days to 14 days. And it was due to the shortening of manufacturing time from 7 days to 5 days. The power of process improvement. Initiation, selection, transduction, feeding, expansion, harvest – all in 5 days. Impressive.

Thank you Lung-I Cheng for facilitating this robust discussion at Reuters Events Pharma about the value of #patient engagement in #cell and #gene therapy development. Key takeaways included: *Innovative study designs, such as leveraging #RWE, is needed to develop treatments for rare diseases which often have small patient populations. *Leveraging information from #FDA's patient focused drug development meetings is important to understanding the patient experience. *The rapid development of #CGTs is a paradigm shift for many regulating bodies, and risk-based flexability is needed to ensure timely #patient #access. *Long-term patient follow up remains a challenge, but the value of capturing patient #data remains a priority. Fellow Panelists: Olga Granaturova, Co-founder, President, PriveBio Jeffrey Meckler, Chief Executive Officer, Indaptus Therapeutics Jason Lott, MD MSHP MHS FAAD, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer Special thanks to my colleagues American Society of Gene & Cell Therapy for supporting my participation at events on this important topic. #ASGCT #ASGCTadvocacy #CellTherapy #GeneTherapy

Epigenetics Update – “ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion” https://bit.ly/3OcnMaG These findings uncover ACSS2 and KAT2A as hitherto unidentified lactyl-CoA synthetase and lactyltransferase, respectively, and the significance of the ACSS2-KAT2A coupling in gene expression and tumor development. #Epigenetics #Lactylation #HisMods #Chromatin --- High-resolution insights with no cell sorting; find out more at http://epigenome.us

Both of our powerhouse Senior Directors of Product Management mRNA hit the stage this past week, reaching the top innovators and leaders in the mRNA industry. Thursday, Tao Lu presented “From Template to Final Product: Innovative Strategies for mRNA Manufacturing a 12th International mRNA Health Conference. Today, Nathan Spangler,  joined a panel discussion focused on manufacturing and how the mRNA sector is overcoming the bottlenecks experienced by the cell and gene therapy industry at the inaugural annual meeting of the Alliance for mRNA Medicines, AMM Ascent. What a week for our mRNA team!